Bioregenx (BRGX) Accumulated Expenses (2021 - 2026)

Bioregenx's Accumulated Expenses history runs 6 years deep, the most recent figure standing at $386754.0 for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 24.83% year-over-year to $386754.0 in Q1 2026; TTM through Mar 2026 was $386754.0, a 24.83% decrease from a year earlier, with the FY2025 full-year figure at $434370.0, down 4.1% from the prior year.
• Accumulated Expenses retreated to $386754.0 in Q1 2026 per BRGX's latest filing, from $434370.0 in the prior quarter.
• Across five years, Accumulated Expenses topped out at $514531.0 in Q1 2025 and bottomed at $19721.0 in Q4 2022.
• The 5-year median for Accumulated Expenses is $383676.5 (2025), against an average of $297231.6.
• Across the five-year window, Accumulated Expenses surged 1657.91% in 2023 and dropped 24.83% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $19721.0 in 2022, then jumped by 1657.91% to $346677.0 in 2023, then surged by 30.66% to $452960.0 in 2024, then retreated by 4.1% to $434370.0 in 2025, then decreased by 10.96% to $386754.0 in 2026.
• Per Business Quant, the three latest BRGX Accumulated Expenses figures stand at $386754.0 (Q1 2026), $434370.0 (Q4 2025), and $380599.0 (Q3 2025).